These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36266539)

  • 41. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
    Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
    Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.
    Kim SR; Hasunuma T; Sato O; Okada T; Kondo M; Azuma J
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S5-17. PubMed ID: 22120090
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study.
    Andersen K; Hartman D; Peppard T; Hermann D; Van Ess P; Lefkowitz M; Trapani A
    J Clin Hypertens (Greenwich); 2012 Sep; 14(9):580-7. PubMed ID: 22947355
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects.
    Vernillet L; Greene SA; Kamin M
    Clin Pharmacol Drug Dev; 2020 May; 9(4):428-443. PubMed ID: 32087001
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.
    Calhoun DA; White WB; Krum H; Guo W; Bermann G; Trapani A; Lefkowitz MP; Ménard J
    Circulation; 2011 Nov; 124(18):1945-55. PubMed ID: 21986283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.
    Smith PF; Krishnarajah J; Nunn PA; Hill RJ; Karr D; Tam D; Masjedizadeh M; Funk JO; Gourlay SG
    Br J Clin Pharmacol; 2017 Nov; 83(11):2367-2376. PubMed ID: 28636208
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety, Pharmacokinetics, and Pharmacodynamics of TD-0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects.
    Kanodia J; Lo A; Baldwin RM; Colley K; Zhou K; Bourdet DL
    Clin Transl Sci; 2020 Nov; 13(6):1307-1315. PubMed ID: 32506827
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.
    Zhou J; Limsakun T; Yin O; Warren V; Zamora C; Atiee G; Kochan J; Pav J; Kobayashi F; Vashi V; Dishy V
    J Clin Pharmacol; 2019 Dec; 59(12):1669-1677. PubMed ID: 31243790
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety, tolerability, and pharmacokinetics of the selective prostacyclin receptor agonist ralinepag in single and multiple dosing studies of an immediate-release oral formulation in healthy volunteers.
    Grundy JS; King CD; Adams JW; Cabell CH
    Pulm Circ; 2020; 10(2):2045894020922814. PubMed ID: 32489643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emerging Therapies for Treatment-Resistant Hypertension: A Review of Lorundrostat and Related Selective Aldosterone Synthase Inhibitors.
    Feldman JM; Frishman WH; Aronow WS
    Cardiol Rev; 2024 Feb; ():. PubMed ID: 38358268
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.
    Kubitza D; Heckmann M; Distler J; Koechel A; Schwers S; Kanefendt F
    Br J Clin Pharmacol; 2022 Jul; 88(7):3447-3462. PubMed ID: 35014061
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
    Jung J; Choi S; Cho SH; Ghim JL; Hwang A; Kim U; Kim BS; Koguchi A; Miyoshi S; Okabe H; Bae KS; Lim HS
    Clin Ther; 2010 Jun; 32(6):1178-87. PubMed ID: 20637970
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers.
    Rocha JF; Santos A; Gama H; Moser P; Falcão A; Pressman P; Wallace Hayes A; Soares-da-Silva P
    Clin Pharmacol Ther; 2022 Feb; 111(2):391-403. PubMed ID: 33998672
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.
    Fossler MJ; Schmith V; Greene SA; Lohmer L; Kramer MS; Arscott K; James IE; Demitrack MA
    CNS Drugs; 2020 Aug; 34(8):853-865. PubMed ID: 32676977
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects.
    Takizawa M; Cerneus D; Michon I; Rijnders S; van der Heide D; Meijer J; Stoelzel M; Sato Y
    Adv Ther; 2020 Sep; 37(9):3878-3900. PubMed ID: 32681461
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.
    Cai TQ; Stribling S; Tong X; Xu L; Wisniewski T; Fontenot JA; Struthers M; Akinsanya KO
    J Pharmacol Toxicol Methods; 2015; 71():137-46. PubMed ID: 25304940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.